Trial Profile

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Ceralasertib (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
Indications Carcinoma; Small cell lung cancer
Focus Therapeutic Use

02 Jan 2026 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
02 Jan 2026 Planned primary completion date changed from 1 Nov 2025 to 1 Mar 2026.
14 Oct 2025 Planned End Date changed from 1 Sep 2025 to 1 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com